Cover Image
市场调查报告书

全球非小细胞肺癌 (NSCLC) 市场

Global Non-Small Cell Lung cancer Market Research and Forecast 2018-2023

出版商 Orion Market Research Pvt Ltd 商品编码 611065
出版日期 内容信息 英文
商品交期: 最快1-2个工作天内
价格
Back to Top
全球非小细胞肺癌 (NSCLC) 市场 Global Non-Small Cell Lung cancer Market Research and Forecast 2018-2023
出版日期: 2018年01月10日 内容信息: 英文
简介

本报告提供全球非小细胞肺癌(NSCLC) 市场相关调查,汇整市场概要和各市场区隔,各地区趋势,及加入此市场的主要企业的简介等数据。

第1章 报告的摘要

第2章 市场概要与趋势

  • 定义
  • 分析师的见解与目前市场趋势
  • 法律规章
  • 专利分析

第3章 市场决策因素

  • 促进要素
  • 阻碍要素
  • 机会

第4章 市场区隔

  • 各类型市场
    • 腺癌
    • 扁平表皮细胞癌症
    • 大细胞癌症
  • 不同治疗市场
    • 化疗
    • 标靶治疗
    • 放射治疗
    • 手术
    • 冷冻治疗
    • 其他
  • 各诊断市场
    • 计算机断层扫描
    • X光扫描
    • 痰液细胞学检查
    • 支气管镜
    • 实验室检验
    • 胸腔镜检验
    • 其他
  • 不同治疗市场
    • 综合医院
    • 癌症研究中心

第5章 竞争环境

  • 策略分析
  • 企业分析

第6章 各地区分析

  • 北美
  • 欧洲
  • 亚太地区
  • 其他各国

第7章 企业简介

  • ABBVIE
  • ARQULE INC.
  • ASTRAZENECA PLC
  • BAYER
  • BOEHRINGER
  • BRISTOL-MYERS SQUIBB
  • CELGENE
  • DAIICHI SANKYO CO. LTD.
  • EISAI
  • ELI LILLY AND COMPANY
  • GENENTECH
  • GLAXOSMITH
  • MERCK & CO. INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER
  • QIAGEN N.V. COMPANY
  • PHARMACYCLICS
  • ROCHE
  • SANOFI
  • TEVA PHARMACEUTICALS
  • VENTANA
  • VALEANT PHARMACEUTICALS INC.
  • VARIAN MEDICAL SYSTEMS INC.
目录
Product Code: OMR2017206

Non-small cell lung cancer market is anticipated to grow at a CAGR of 8.6% by 2023. Lung cancer starts when cells of the lung become abnormal and begin to grow out of control. As more cancer cells develop, they form into a tumor and spread to other areas of the body. The non-small cell lung cancer is a type of lung cancer. Several factors that cause lung cancer include pollution, smoking, passive smoking and other factors. Hereditary causes of cancer is another factor that drives the global non-small cell lung cancer diagnostics and therapeutics market.

Rising pollution due to the amount of carbon particles inhaled by humans cause several problems including lung cancer. Several factors that drive the market include robust healthcare expenditure within developed countries, increasing pollution, government initiatives for lung cancer, and rising cases of smoking. There are several signs and symptoms of lung cancer such as coughing up blood, weight loss, chest pain, shortness of breath and others. According to the National Cancer Institute, an estimated number of deaths due to lung cancer was around 155,000 in 2017.

The non-small cell lung cancer diagnosis and therapeutics market has been segmented based on by type, by treatment, by diagnosis, by stages and by end user. On the basis of type, the market has been bifurcated into squamous cell carcinoma, large cell carcinoma, adenocarcinoma and others. According to therapy, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery and others. Based on diagnosis, the market has been bifurcated into CT-scan, X-rays, laboratory test, bronchoscopy, sputum cytology, thoracoscopy and others. On the basis of end user, the market has been bifurcated into multispecialty hospitals and cancer research centers.

Geographically, the worldwide non-small cell lung cancer diagnosis and therapeutics market is divided into North America, Europe, Asia-Pacific, and Rest of the World. Asia Pacific market is considered to be the fastest growing market globally. The rise in the number of cancer patients in the APAC region is considered to rise eventually enabling the lung cancer diagnosis and therapeutics market to grow. North America and Europe are considered to be the dominating markets due to various factors such as high healthcare expenditure, development in technology, support from government, rise in key players and various other factors.

The key players in the non-small cell lung cancer diagnosis and therapeutics market include Astrazeneca PLC, Eli lilly and company Sanofi-Aventis, Arqule Inc, Daiichi Sankyo co. Ltd, Celgene, Merck, Pfizer, Ventana, Roche, Genentech, Glaxosmith, Boehringer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie, Pharmacyclics.

MARKET SEGMENTATION:

Global non-small cell lung cancer diagnosis and therapeutics market is segmented on the basis of, type, by therapies, by, diagnosis, by end user and regional outlook.

  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Type
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Therapies
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Diagnosis
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By End User
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Region

THE REPORTS COVERS:

  • Comprehensive research methodology of Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • Insights about market determinants which are stimulating the Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

  • 1. REPORT SUMMARY
  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
  • 1.2.1. BY SEGMENTS
  • 1.2.2. BY GEOGRAPHY
  • 1.2.3. BY STAKEHOLDERS
  • 2. MARKET OVERVIEW AND INSIGHTS
  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
  • 2.2.1. KEY FINDINGS
  • 2.2.2. RECOMMENDATION
  • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
  • 2.3.1. UNITED STATES
  • 2.3.2. EUROPEAN UNION
  • 2.3.3. CHINA
  • 2.3.4. INDIA
  • 2.3.5. REST OF THE WORLD
  • 2.4. PATENT ANALYSIS
  • 3. MARKET DETERMINANT
  • 3.1. MOTIVATORS
  • 3.1.1. RISING UTILIZATION OF COMBINE THERAPIES
  • 3.1.2. GOVERNMENT INITIATIVES FOR IMPROVING THE AWARENESS AMONG INDIVIDUALS
  • 3.1.3. RISING LEVELS POLLUTION DUE TO URBANIZATION INCREASES CASES OF LUNG CANCER
  • 3.1.4. HIGH PREVALANCE OF LUNG CANCER AND LUNG RELATED ISSUES DUE SMOKING
  • 3.1.5. INVESTMENTS IN CANCER DRUG DISCOVERY AND BIOMARKER IDENTIFICATION
  • 3.2. RESTRAINTS
  • 3.2.1. HIGH COST ASSOCIATED WITH LUNG CANCER THERAPIES
  • 3.2.2. UNMET NEED & DIAGNOSIS IN UNDER DEVELOPED NATION
  • 3.2.3. ADVERSE EFFECTS OF DRUGS DURING TREATMENT
  • 3.3. OPPORTUNITIES
  • 3.3.1. R&D IN THE THERAPIES AND DRUGS
  • 3.3.2. STRATEGIC ALLIANCE FOR LATE-STAGE PIPELINE
  • 4. MARKET SEGMENTATION
  • 4.1. GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY TYPE
  • 4.1.1. ADENOCARCINOMAS
  • 4.1.2. SQUAMOUS CELL CARCINOMA
  • 4.1.3. LARGE CELL CARCINOMAS
  • 4.1.4. OTHERS
  • 4.2. GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY THERAPY
  • 4.2.1. CHEMOTHERAPY
  • 4.2.2. TARGETED THERAPY
  • 4.2.3. RADIATION THERAPY
  • 4.2.4. SURGERY
  • 4.2.5. CRYOSURGERY
  • 4.2.6. OTHERS
  • 4.3. GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY DIAGNOSIS
  • 4.3.1. CT SCAN
  • 4.3.2. X-RAYS
  • 4.3.3. SPUTUM CYTOLOGY
  • 4.3.4. BRONCHOSCOPY
  • 4.3.5. LABORATORY TESTS
  • 4.3.6. THORACOSCOPY
  • 4.3.7. OTHERS
  • 4.4. GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY END USER
  • 4.4.1. MULTISPECIALITY HOSPITALS
  • 4.4.2. CANCER RESEARCH CENTERS
  • 5. COMPETITIVE LANDSCAPE
  • 5.1. STRATEGY ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS
  • 6. REGIONAL ANALYSIS
  • 6.1. NORTH AMERICA
  • 6.1.1. UNITED STATES
  • 6.1.2. CANADA
  • 6.2. EUROPE
  • 6.2.1. UNITED KINGDOM
  • 6.2.2. FRANCE
  • 6.2.3. GERMANY
  • 6.2.4. ITALY
  • 6.2.5. SPAIN
  • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
  • 6.3.1. INDIA
  • 6.3.2. CHINA
  • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD
  • 7. COMPANY PROFILES
  • 7.1. ABBVIE
  • 7.2. ARQULE INC.
  • 7.3. ASTRAZENECA PLC
  • 7.4. BAYER
  • 7.5. BOEHRINGER
  • 7.6. BRISTOL-MYERS SQUIBB
  • 7.7. CELGENE
  • 7.8. DAIICHI SANKYO CO. LTD.
  • 7.9. EISAI
  • 7.10. ELI LILLY AND COMPANY
  • 7.11. GENENTECH
  • 7.12. GLAXOSMITH
  • 7.13. MERCK & CO. INC.
  • 7.14. NOVARTIS INTERNATIONAL AG
  • 7.15. PFIZER
  • 7.16. QIAGEN N.V. COMPANY
  • 7.17. PHARMACYCLICS
  • 7.18. ROCHE
  • 7.19. SANOFI
  • 7.20. TEVA PHARMACEUTICALS
  • 7.21. VENTANA
  • 7.22. VALEANT PHARMACEUTICALS INC.
  • 7.23. VARIAN MEDICAL SYSTEMS INC.

List of Tables

  • TABLE # 1 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY, 2017-2023($MILLION)
  • TABLE # 2 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION)
  • TABLE # 3 GLOBAL ADENOCARCINOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION) 2022, ($ MILLION)
  • TABLE # 4 GLOBAL SARCOMAS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 5 GLOBAL LARGE CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 7 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023($ MILLION)
  • TABLE # 8 GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 9 GLOBAL TARGETED THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 10 GLOBAL RADIOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 11 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 12 GLOBAL CRYOSURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 13 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 14 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS, 2017-2023, ($ MILLION)
  • TABLE # 15 GLOBAL CT-SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 16 GLOBAL X-RAYS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 17 GLOBAL SPUTUM CYTOLOGY SCREENING MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 18 GLOBAL BRONCHOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 19 GLOBAL LABORATORY TEST MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 20 GLOBAL THORACOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 21 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 22 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023, ($ MILLION)
  • TABLE # 23 GLOBAL MULTISPECIALTY HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 24 GLOBAL CANCER RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLION)
  • TABLE # 25 MERGER AND ACQUISITION
  • TABLE # 26 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY GEOGRAPHY 2016-20122($ MILLION)
  • TABLE # 27 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($MILLION)
  • TABLE # 28 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023($MILLION)
  • TABLE # 29 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 30 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)
  • TABLE # 31 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)
  • TABLE # 32 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($MILLION)
  • TABLE # 33 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023($MILLION)
  • TABLE # 34 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 35 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)
  • TABLE # 36 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)
  • TABLE # 37 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($MILLION)
  • TABLE # 38 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023($MILLION)
  • TABLE # 39 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 40 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)
  • TABLE # 41 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)
  • TABLE # 42 REST OF THE WORLD NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($MILLION)
  • TABLE # 43 REST OF THE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY THERAPY 2017-2023($MILLION)
  • TABLE # 44 REST OF THE WORLD NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 45 REST OF THE WORLD NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)

List of Figures

  • FIGURE # 1 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE, BY TYPE 2017 AND 2023, (IN %)
  • FIGURE # 2 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE, BY THERAPY 2017 AND 2023, (IN %)
  • FIGURE # 3 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE, BY DIAGNOSIS 2017 AND 2023, (IN %)
  • FIGURE # 4 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE, BY END USER 2017 AND 2023, (IN %)
  • FIGURE # 5 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE, BY GEOGRAPHY 2017 AND 2023, (IN %)
  • FIGURE # 6 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 7 US NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 8 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 9 EUROPEAN NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 10 UK NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 11 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 12 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 13 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 14 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 15 ROE NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 16 ASIA PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 17 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 18 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 19 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 20 ROAPAC NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 21 REST OF THE WORLD NON-SMALL CELL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2017-2023 ($
Back to Top